حدد سهمًا أو عملة مشفرة في شريط البحث للحصول على ملخص
Embla Medical hf
EMBLAEmbla Medical hf., together with its subsidiaries, provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It operates through three segments: Prosthetics, Bracing & Supports, and Patient Care. The Prosthetics segment offers mechanical products, such as lower limb prosthetics and finger prostheses; and bionic products microprocessor-controlled feet, knees, hands, liners, fingers, and other components integrated. Its Bracing & Supports segment provides bracing and supports products, such as supporting devices for spinal, hip, knee, foot, ankle, and hands for therapeutic and preventative purposes; and injury solutions for people recovering from fractures and ligament injuries. The Patient Care segment offers prosthetics for people with lower and upper limb loss or limb difference; and orthotics for neurological, gait, and musculoskeletal conditions. It serves specialized healthcare providers, including orthopedic and prosthetic clinics, hospitals, and surgery centers. The company sells its products through its direct sales networks and distributors. The company was formerly known as Össur hf. and changed its name to Embla Medical hf. in April 2024. Embla Medical hf. was incorporated in 1971 and is headquartered in Reykjavik, Iceland. Embla Medical hf. is a subsidiary of William Demant Invest A/S. Address: GrjOthAls 1-5, Reykjavik, Iceland
Analytics
سعر الهدف في وول ستريت
257.5 DKKنسبة السعر إلى الأرباح
30.5155العائد الربحي
–السنة الحالية
العام الماضي
الربع الحالي
الربع الأخير
السنة الحالية
العام الماضي
الربع الحالي
الربع الأخير
الشخصيات الرئيسية EMBLA
تحليلات الأرباح EMBLA
نمو الأرباح على مدى 5 سنوات
–النمو المستمر
3 سنينمعدل الدفع 5 سنوات في المتوسط
7 %تاريخ الأرباح EMBLA
تقييم الأسهم EMBLA
المالية EMBLA
نتائج | 2019 | ديناميات |